<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458512459289</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458512459289</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Hagemeier</surname><given-names>Jesper</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512459289">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Yeh</surname><given-names>E Ann</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512459289">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Brown</surname><given-names>Mari Heininen</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512459289">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bergsland</surname><given-names>Niels</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512459289">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Dwyer</surname><given-names>Michael G</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512459289">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Carl</surname><given-names>Ellen</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512459289">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Weinstock-Guttman</surname><given-names>Bianca</given-names></name>
<xref ref-type="aff" rid="aff3-1352458512459289">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Zivadinov</surname><given-names>Robert</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512459289">1</xref>
<xref ref-type="aff" rid="aff3-1352458512459289">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458512459289"><label>1</label>Buffalo Neuroimaging Analysis Center, University at Buffalo, USA</aff>
<aff id="aff2-1352458512459289"><label>2</label>Neurology Department, Women and Children’s Hospital, USA</aff>
<aff id="aff3-1352458512459289"><label>3</label>The Jacobs Neurological Institute, University at Buffalo, USA</aff>
<author-notes>
<corresp id="corresp1-1352458512459289">Robert Zivadinov, Department of Neurology, School of Medicine and Biomedical Sciences, Buffalo Neuroimaging Analysis Center, 100 High St., Buffalo, NY 14203, USA. Email: <email>rzivadinov@bnac.net</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>5</issue>
<fpage>567</fpage>
<lpage>576</lpage>
<history>
<date date-type="received">
<day>1</day>
<month>3</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>15</day>
<month>5</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>2</day>
<month>8</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1352458512459289">
<title>Objective:</title>
<p>The objective of this paper is to assess abnormal phase values, indicative of increased iron content, using susceptibility-weighted imaging (SWI)-filtered phase of the subcortical deep gray matter (SDGM) in adolescent multiple sclerosis (MS) and other neurological disorders (OND) patients, and in healthy controls (HC).</p>
</sec>
<sec id="section2-1352458512459289">
<title>Methods:</title>
<p>Twenty adolescent MS and eight adolescent OND patients and 21 age- and sex-matched HC were scanned on a 3T GE scanner. Mean phase of abnormal phase tissue (MP-APT), MP-APT volume, normal phase tissue volume (NPTV) and normalized volume measurements were obtained for total SDGM, as well as specific structures separately.</p>
</sec>
<sec id="section3-1352458512459289">
<title>Results:</title>
<p>Significantly increased MP-APT (28.2%, <italic>p</italic>&lt;.001) and MP-APT volume (82.7%, <italic>p</italic>&lt;.001), and decreased NPTV (−23.3%, <italic>p</italic>&lt;.001) and normalized volume (−15.5%, <italic>p</italic>&lt;.001) in the pulvinar nucleus of the thalamus was found in MS patients compared to HC. MP-APT in MS patients was also increased in total SDGM (<italic>p</italic>=.012) and thalamus (<italic>p</italic>=.044). Compared to OND patients, MS patients had increased MP-APT volume in the pulvinar nucleus of the thalamus (<italic>p</italic>=.044) and caudate (<italic>p</italic>=.045). Increased MP-APT of the SDGM structures were associated with increased T2 and T1 lesion burden and brain atrophy in MS patients.</p>
</sec>
<sec id="section4-1352458512459289">
<title>Conclusion:</title>
<p>Adolescent MS patients showed increased iron content in the SDGM compared to OND patients and HC.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Adolescent multiple sclerosis</kwd>
<kwd>abnormal phase</kwd>
<kwd>iron deposition</kwd>
<kwd>susceptibility-weighted imaging</kwd>
<kwd>phase images</kwd>
<kwd>atrophy</kwd>
<kwd>inflammation</kwd>
<kwd>pediatric</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section5-1352458512459289" sec-type="intro">
<title>Introduction</title>
<p>Extensive involvement of cortical and subcortical deep gray matter (SDGM) has been described in patients with multiple sclerosis (MS).<sup><xref ref-type="bibr" rid="bibr1-1352458512459289">1</xref></sup> Iron deposition in SDGM structures, such as the thalamus, putamen, caudate and globus pallidus, has been detected in MS patients both histologically<sup><xref ref-type="bibr" rid="bibr2-1352458512459289">2</xref></sup> and in vivo by means of different magnetic resonance imaging (MRI) techniques.<sup><xref ref-type="bibr" rid="bibr3-1352458512459289">3</xref>,<xref ref-type="bibr" rid="bibr4-1352458512459289">4</xref></sup> Recently, it has been demonstrated that iron accumulation in the SDGM of MS patients is confined to identical SDGM areas, where volume loss occurs,<sup><xref ref-type="bibr" rid="bibr3-1352458512459289">3</xref></sup> and that it can precede structure-specific atrophy at the earliest clinical stages of the disease.<sup><xref ref-type="bibr" rid="bibr5-1352458512459289">5</xref></sup> However, it is unclear whether iron deposition is primary or secondary to inflammation in patients with MS.</p>
<p>Previous studies have reported that juvenile MS patients show relatively mild whole brain, gray-matter (GM) or white-matter (WM) involvement.<sup><xref ref-type="bibr" rid="bibr6-1352458512459289">6</xref></sup> However, there have been reports of region-specific GM volume loss in the thalamus of adolescent MS patients.<sup><xref ref-type="bibr" rid="bibr7-1352458512459289">7</xref><xref ref-type="bibr" rid="bibr8-1352458512459289"/>–<xref ref-type="bibr" rid="bibr9-1352458512459289">9</xref></sup> The extent of iron deposition in the SDGM has been extensively investigated in adult<sup><xref ref-type="bibr" rid="bibr3-1352458512459289">3</xref>,<xref ref-type="bibr" rid="bibr4-1352458512459289">4</xref></sup> but not in adolescent MS patients. A recent report showed increased T2 hypointensity in the left caudate of adolescent MS patients.<sup><xref ref-type="bibr" rid="bibr10-1352458512459289">10</xref></sup></p>
<p>Susceptibility-weighted imaging (SWI)-filtered phase has been proposed as a method for measuring in vivo iron deposition.<sup><xref ref-type="bibr" rid="bibr3-1352458512459289">3</xref>,<xref ref-type="bibr" rid="bibr11-1352458512459289">11</xref></sup> It takes advantage of local magnetic field changes caused by paramagnetic substances within the brain, such as ferritin, an integral iron storage protein, which influence the frequency of proton spin. Because of this, SWI-filtered phase imaging results in a type of contrast enhancement, giving rise to a metric of the density of iron.<sup><xref ref-type="bibr" rid="bibr12-1352458512459289">12</xref></sup></p>
<p>In this study, we investigated the local distribution of abnormal iron content in the SDGM in adolescent MS and other neurological disorders (OND) patients as well as in healthy controls (HC), using SWI-filtered phase. In addition, atrophy measures of SDGM structures were compared between study groups. Moreover, we examined the relevance of these metrics in MS patients by investigating their associations with standard MRI and clinical outcomes.</p>
</sec>
<sec id="section6-1352458512459289" sec-type="methods">
<title>Methods</title>
<sec id="section7-1352458512459289">
<title>Subjects</title>
<p>This study included 20 prospectively enrolled adolescent MS patients<sup><xref ref-type="bibr" rid="bibr13-1352458512459289">13</xref></sup> with relapsing–remitting (RR) disease course, and two age- and sex-matched control groups (eight OND patients and 21 HC). Participants were excluded if they had a relapse or were treated with steroids within the month preceding study entry or had any pre-existing medical conditions known to be associated with brain pathology. Diagnoses of OND patients included three patients with a neurovascular disorder (transitory ischemic attack, migraine headache and central nervous system (CNS) vasculitis), two with a neuromuscular disorder (restless leg syndrome) and three with a neuroinflammatory disorder (acute disseminated encephalomyelitis). HC subjects were volunteers who underwent neurological examination and had no history of neurologic or psychiatric disorders. The study protocol received approval from the local Institutional Review Board and all participants provided their written informed consent prior to examination.</p>
</sec>
<sec id="section8-1352458512459289">
<title>Image acquisition</title>
<p>Scans were performed on a 3T GE Signa Excite HD 12.0 (General Electric, Milwaukee, WI, USA), using a multi-channel head and neck (HDNV) coil. SWI was acquired using a three-dimensional (3D) flow-compensated GRE sequence with 64 locations, 2 mm thickness, a 512×192 matrix, field of view (FOV)=25.6 cm × 19.2 cm (512×256 matrix with Phase FOV=0.75), for an in-plane resolution of 0.5 mm × 1 mm (flip angle (FA)=12; echo and repetition times (TE/TR)=22/40 ms; acquisition time (AT)=8:46 min:sec).<sup><xref ref-type="bibr" rid="bibr3-1352458512459289">3</xref></sup></p>
<p>In addition to SWI, the following sequences were acquired: two-dimensional (2D) multi-planar dual fast spin-echo (FSE) proton density (PD) and T2-weighted image (WI; TE1/TE2/TR=9/98/5300 ms; FA=90<sup>o</sup>; and echo train length (ETL)=14); fluid-attenuated inversion-recovery (FLAIR; TE/TI/TR=120/2100/8500 ms (inversion time, TI); FA=90<sup>o</sup>; ETL=24); 3D high resolution (HIRES) T1-WI using a fast spoiled gradient echo (FSPGR) with magnetization-prepared inversion recovery (IR) pulse (TE/TI/TR=2.8/900/5.9 ms, FA=10); and spin echo (SE) T1-WI (TE/TR=16/600 ms, FA=90). All scans were prescribed parallel to the subcallosal line in an axial-oblique orientation. One average was used for all sequences.</p>
<p>All sequences except SWI were obtained with a 256×192 matrix (freq × phase), FOV of 25.6 cm × 19.2 cm (256×256 matrix with Phase FOV=0.75), for an in-plane resolution of 1 mm × 1 mm. For all 2D scans (PD/T2, FLAIR and SE T1), 48 slices were collected, with a thickness of 3 mm and no gap between slices. For the 3D HIRES IR-FSPGR, 184 1 mm thick locations were acquired, resulting in isotropic resolution.</p>
</sec>
<sec id="section9-1352458512459289">
<title>Image analyses</title>
<p>Analyses were performed by operators who were unaware of the participants’ disease status.</p>
<sec id="section10-1352458512459289">
<title>Abnormal phase identification</title>
<p>SDGM structures were segmented using a combination of semi-automated edge contouring and FMRIB’s integrated registration and segmentation tool (FIRST) on 3D T1-WI.<sup><xref ref-type="bibr" rid="bibr14-1352458512459289">14</xref></sup> Specifically, the thalamus, caudate, putamen, globus pallidus, hippocampus, amygdala and nucleus accumbens were identified in this way.<sup><xref ref-type="bibr" rid="bibr15-1352458512459289">15</xref></sup> Structures not identifiable by FIRST, such as the red nucleus, pulvinar nucleus of the thalamus and substantia nigra, were identified semi-automatically using JIM5 (Xinapse Systems Ltd, Northamptonshire, UK) on the most representative slice for each subject.<sup><xref ref-type="bibr" rid="bibr15-1352458512459289">15</xref></sup> Using these methods, it has previously been determined that segmentation of separate SDGM regions can be reliably reproduced.<sup><xref ref-type="bibr" rid="bibr3-1352458512459289">3</xref></sup></p>
<p>A detailed overview of SWI processing, reproducibility and analysis methods is provided elsewhere.<sup><xref ref-type="bibr" rid="bibr3-1352458512459289">3</xref></sup> Briefly, using the SWI-filtered phase images, processing is performed to identify voxels likely to contain iron, based on their mean phase values (<xref ref-type="fig" rid="fig1-1352458512459289">Figure 1</xref>). Normal reference phase values (means and standard deviations) for each SDGM structure are determined.<sup><xref ref-type="bibr" rid="bibr3-1352458512459289">3</xref></sup> Images are thresholded to retain only the voxels with phase values lower than two standard deviations below the reference mean values of each structure. As a measure of the degree of phase decrease, the mean value of sub-threshold voxels of the mean phase of the abnormal phase tissue (MP-APT) is calculated. This yields structure-specific maps of voxels with abnormal phase. More negative MP-APT values suggest increased iron content within a region. Mean values are presented in radians. In addition, the abnormal phase tissue volume (MP-APT volume) is determined by retaining all voxels with abnormal phase for each structure. On the other hand, normal phase tissue volume (NPTV) is obtained by subtracting the MP-APT volume of a particular structure from the total normalized volume of the same structure.</p>
<fig id="fig1-1352458512459289" position="float">
<label>Figure 1.</label>
<caption>
<p>Individual susceptibility-weighted imaging (SWI)-filtered phase images were aligned with the Montreal Neurological Institute (MNI) atlas and then averaged together to create mean phase images for 21 healthy controls (left), 20 multiple sclerosis (MS) patients (middle) and eight patients with other neurologic diseases (OND) (right). The pulvinar nucleus of thalamus (arrow) appears bilaterally brighter in the MS group image and corresponds to the mean phase of the abnormal phase tissue (MP-APT) findings (<xref ref-type="table" rid="table2-1352458512459289">Table 2</xref>).</p>
</caption>
<graphic xlink:href="10.1177_1352458512459289-fig1.tif"/></fig>
</sec>
<sec id="section11-1352458512459289">
<title>Global atrophy and lesion analyses</title>
<p>The SIENAX cross-sectional software tool (version 2.6) was used, with correction for T1-hypointensity misclassification, for brain extraction and tissue segmentation on 3D-T1-WI.<sup><xref ref-type="bibr" rid="bibr3-1352458512459289">3</xref></sup> We acquired normalized volume measures of the whole brain (NBV), GM (NGMV), white matter (NWMV) and lateral ventricles (NLVV), as described previously. Moreover, the T2- and T1- lesion volumes (LV) were measured on FLAIR and SE T1-WI, respectively, using a semi-automated edge detection contouring/thresholding technique, as described previously.<sup><xref ref-type="bibr" rid="bibr16-1352458512459289">16</xref></sup> Normalized volumes were obtained for all SDGM structures with FIRST on 3D-T1-WI.<sup><xref ref-type="bibr" rid="bibr15-1352458512459289">15</xref></sup></p>
</sec>
</sec>
<sec id="section12-1352458512459289">
<title>Statistical analysis</title>
<p>Data analysis was conducted using PASW Statistics, version 18.0 (IBM Corp., Somers, NY, USA). Differences in demographic characteristics and atrophy measures between study groups were assessed using the Chi-square and analysis of variance tests. Because MP-APT was not normally distributed as determined by Shapiro-Wilks test (<italic>p</italic>&lt;.01), the Kruskal-Wallis test was used to compare group-wise differences of this variable. MP-APT volume, normalized volume and NPTV measures were compared using analysis of variance. In order to limit the number of multiple comparisons, pair-wise post hoc analyses were carried out only for those variables with a trend <italic>p</italic>-value level of <italic>p</italic>&lt;.1 in group-wise analyses, by using the Student’s <italic>t</italic>-test and Mann Whitney U test, where appropriate. No significant MP-APT, MP-APT volume or volume differences were observed between the right and left hemispheres; therefore, data were combined in all analyses. We employed Spearman correlation coefficients to assess the relationship between SDGM MP-APT, MP-APT volume, NPTV and normalized volume with other MRI and clinical variables. Because of the exploratory nature of the study, we considered nominal <italic>p</italic>-values of <italic>p</italic>&lt;.05 as significant, using two-tailed testing.</p>
</sec>
</sec>
<sec id="section13-1352458512459289" sec-type="results">
<title>Results</title>
<p><xref ref-type="table" rid="table1-1352458512459289">Table 1</xref> shows demographic, clinical and MRI characteristics of the study groups. Eighteen (18) adolescent MS patients were Caucasian, whereas two were African-American. Fifteen (75%) adolescent MS patients were taking disease-modifying therapy (10=interferon beta-1a, two=glatiramer acetate, one=natalizumab, one= cyclophosphamide, and one=Interferon beta-1b) for an average time of 9.4 months (SD=9.9). None of the brain volume measures differed significantly between groups. All HC had normal brain MRI scans. No lesions were found on conventional MRI sequences in the SDGM of MS or OND patients.</p>
<table-wrap id="table1-1352458512459289" position="float">
<label>Table 1.</label>
<caption>
<p>Clinical and demographic characteristics of healthy control (HC) subjects and patients with adolescent multiple sclerosis (MS) or other neurologic diseases (OND).</p>
</caption>
<graphic alternate-form-of="table1-1352458512459289" xlink:href="10.1177_1352458512459289-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">HC (<italic>n</italic>=21)</th>
<th align="left">Adolescent MS (<italic>n</italic>=20)</th>
<th align="left">Adolescent OND (<italic>n</italic>=8)</th>
<th align="left"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female:male</td>
<td>10:11</td>
<td>11:9</td>
<td>5:3</td>
<td>.753</td>
</tr>
<tr>
<td>Age, mean (SD) median [range]</td>
<td>14.8 (3) 16 [10]</td>
<td>15.6 (2.9) 17 [11]</td>
<td>13.8 (3.1) 14.5 [10]</td>
<td>.326</td>
</tr>
<tr>
<td>Disease duration in years, mean (SD) median [range]</td>
<td>—</td>
<td>3.2 (2.7) 2 [12]</td>
<td>3 (1.1) 3 [3]</td>
<td>.842</td>
</tr>
<tr>
<td>Age of MS onset, mean (SD) median [range]</td>
<td>—</td>
<td>12.4 (3.8) 14.0 [14]</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Number of relapses in past year, mean (SD) median [range]</td>
<td>—</td>
<td>.7 (.9) 0 [3]</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Expanded Disability Status Scale, mean (SD) median [range]</td>
<td>—</td>
<td>1.3 (1.3) 1.3 [4]</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>T2 lesion volume, mean (SD) median</td>
<td>—</td>
<td>12.1 (26.5) 4.3</td>
<td>2.0 (25.4) .7</td>
<td>.299</td>
</tr>
<tr>
<td>T1 lesion volume, mean (SD) median</td>
<td>—</td>
<td>.9 (3.4) 0</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Normalized brain volume, mean (SD) median</td>
<td>1727.8 (76.2) 1731.4</td>
<td>1682.7 (68.8) 1687.1</td>
<td>1731.8 (104.9) 1720.7</td>
<td>.161</td>
</tr>
<tr>
<td>Normalized gray matter volume, mean (SD) median</td>
<td>904.2 (52.2) 896.7</td>
<td>882.6 (50.8) 881.4</td>
<td>891.4 (56.4) 900.4</td>
<td>.438</td>
</tr>
<tr>
<td>Normalized white matter volume, mean (SD) median</td>
<td>823.6 (58.8) 837.2</td>
<td>800.1 (44.7) 809.2</td>
<td>840.3 (59.6) 877.4</td>
<td>.229</td>
</tr>
<tr>
<td>Normalized lateral ventricle volume, mean (SD) median</td>
<td>16.8 (7) 18.6</td>
<td>21.8 (14.5) 18.6</td>
<td>18.9 (11.1) 133.6</td>
<td>.373</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458512459289">
<p><italic>n</italic> = number. Volume measurements are expressed in cubic millimeters. Differences between groups in demographic characteristics and magnetic resonance imaging measures were tested using the analysis of variance, the Student’s <italic>t</italic>-test and chi-square test.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p><xref ref-type="table" rid="table2-1352458512459289">Table 2</xref> shows group-wise and pair-wise differences in the MP-APT values between the three study groups. In group-wise comparisons, significantly increased MP-APT was found in the pulvinar nucleus of the thalamus (<italic>p</italic>&lt;.001, <xref ref-type="fig" rid="fig2-1352458512459289">Figure 2a</xref>) and total SDGM (<italic>p</italic>=.039), while there was also a trend for increased thalamic MP-APT (<italic>p</italic>=.063). Pair-wise comparison revealed significantly increased MP-APT in MS patients compared to HC in the pulvinar nucleus of the thalamus (28.2%, <italic>p</italic>&lt;.001, <italic>d</italic>=.77), total SDGM (11.2%, <italic>p</italic>=.012, <italic>d=.59</italic>) and thalamus (19.2%, <italic>p</italic>=.044, <italic>d=.</italic>65). MS patients showed a trend for increased MP-APT in the pulvinar nucleus of the thalamus (<italic>p</italic>=.075) and thalamus (<italic>p</italic>=.075) compared to OND patients, while no MP-APT differences were found between OND patients and HC.</p>
<table-wrap id="table2-1352458512459289" position="float">
<label>Table 2.</label>
<caption>
<p>Mean phase of the abnormal phase tissue (MP-APT) measurements of subcortical deep gray matter (SDGM) structures of healthy control (HC) subjects and patients with adolescent multiple sclerosis (MS) or other neurologic diseases (OND).</p>
</caption>
<graphic alternate-form-of="table2-1352458512459289" xlink:href="10.1177_1352458512459289-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="4"><bold>MP-APT</bold><hr/></th>
</tr>
<tr>
<th/>
<th align="left">HC (<italic>n</italic>=21) mean (SD)</th>
<th align="left">Adolescent MS (<italic>n</italic>=20) mean (SD)</th>
<th align="left">Adolescent OND (<italic>n</italic>=8) mean (SD)</th>
<th align="left"><bold><italic>p</italic>-value</bold></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total SDGM</td>
<td>−.126 (.028)</td>
<td>−.140<sup><xref ref-type="table-fn" rid="table-fn2-1352458512459289">†</xref></sup> (.019)</td>
<td>−.120 (.025)</td>
<td>.039</td>
</tr>
<tr>
<td>Caudate</td>
<td>−.157 (.011)</td>
<td>−.168 (.047)</td>
<td>−.149 (.007)</td>
<td>.106</td>
</tr>
<tr>
<td>Putamen</td>
<td>−.153 (.048)</td>
<td>−.159 (.042)</td>
<td>−.153 (.041)</td>
<td>.660</td>
</tr>
<tr>
<td>Globus pallidus</td>
<td>−.166 (.017)</td>
<td>−.189 (.054)</td>
<td>−.167 (.026)</td>
<td>.201</td>
</tr>
<tr>
<td>Thalamus</td>
<td>−.078 (.007)</td>
<td>−.093<sup><xref ref-type="table-fn" rid="table-fn2-1352458512459289">†</xref></sup> (.032)</td>
<td>−.077 (.006)</td>
<td>.063</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>−.166 (.061)</td>
<td>−.186 (.068)</td>
<td>−.128 (.017)</td>
<td>.125</td>
</tr>
<tr>
<td>Amygdala</td>
<td>−.191 (.051)</td>
<td>−.248 (.133)</td>
<td>−.208 (.097)</td>
<td>.352</td>
</tr>
<tr>
<td>Nucleus accumbens</td>
<td>−.758 (.26)</td>
<td>−.780 (.22)</td>
<td>−.839 (.059)</td>
<td>.513</td>
</tr>
<tr>
<td>Red nucleus</td>
<td>−.202 (.014)</td>
<td>−.207 (.013)</td>
<td>−.208 (.010)</td>
<td>.772</td>
</tr>
<tr>
<td>Substantia nigra</td>
<td>−.273 (.022)</td>
<td>−.309 (.123)</td>
<td>−.273 (.014)</td>
<td>.603</td>
</tr>
<tr>
<td>Pulvinar nucleus</td>
<td>−.124 (.011)</td>
<td>−.159<sup><xref ref-type="table-fn" rid="table-fn2-1352458512459289">††</xref></sup> (.063)</td>
<td>−.130 (.010)</td>
<td>&lt; .001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1352458512459289">
<p><italic>n</italic> = number. MP-APT is expressed in radians. Differences between groups were tested using the Kruskal-Wallis and Mann-Whitney U tests. * <italic>p</italic>&lt;.05, ** <italic>p</italic>&lt;.01 for OND versus HC; <sup>†</sup> <italic>p</italic>&lt;.05, <sup>††</sup> <italic>p</italic>&lt;.01 for MS versus HC; <sup>‡</sup> <italic>p</italic>&lt;.05, <sup>‡‡</sup> <italic>p</italic>&lt;.01 for MS versus OND.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig2-1352458512459289" position="float">
<label>Figure 2.</label>
<caption>
<p>Differences between healthy controls (HC), adolescent multiple sclerosis (MS) patients, and adolescent patients with other neurological diseases (OND) of the pulvinar nucleus of the thalamus for (a) mean phase of abnormal phase tissue (MP-APT), (b) MP-APT volume, (c) normalized volume and (d) normal phase tissue volume (NPTV).</p>
</caption>
<graphic xlink:href="10.1177_1352458512459289-fig2.tif"/></fig>
<p>Volume measurements of MP-APT yielded similar results, especially in the pulvinar nucleus of the thalamus (<xref ref-type="table" rid="table3-1352458512459289">Table 3</xref> and <xref ref-type="fig" rid="fig2-1352458512459289">Figure 2b</xref>). There was also a trend for increased MP-APT volume in the substantia nigra (<italic>p</italic>=.06) and caudate (<italic>p</italic>=.0.78). Compared to HC, the MP-APT volume of the pulvinar nucleus of the thalamus (82.7%, <italic>p</italic>&lt;.001, <italic>d</italic>=1.53) and substantia nigra (66.5%, <italic>p</italic>=.018, <italic>d</italic>=.83) was significantly increased in MS patients. Furthermore, MS patients also had increased MP-APT volume compared to OND patients in the pulvinar nucleus of the thalamus (52.1%, <italic>p</italic>=.044, <italic>d</italic>=1.11) and caudate (40.9%, <italic>p</italic>=.045, <italic>d</italic>=1.09). No significant MP-APT volume differences were found between OND patients and HC.</p>
<table-wrap id="table3-1352458512459289" position="float">
<label>Table 3.</label>
<caption>
<p>Volume measurements of the mean phase of the abnormal phase tissue (MP-APT) in subcortical deep gray matter (SDGM) structures of healthy control (HC) subjects and patients with adolescent multiple sclerosis (MS) or other neurologic diseases (OND).</p>
</caption>
<graphic alternate-form-of="table3-1352458512459289" xlink:href="10.1177_1352458512459289-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="4"><bold>MP-APT Volume</bold><hr/></th>
</tr>
<tr>
<th/>
<th align="left">HC (<italic>n</italic>=21) mean (SD)</th>
<th align="left">Adolescent MS (<italic>n</italic>=20) mean (SD)</th>
<th align="left">Adolescent OND (<italic>n</italic>=8) mean (SD)</th>
<th align="left"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total SDGM</td>
<td>13.006 (2.171)</td>
<td>13.421 (1.355)</td>
<td>12.49 (1.956)</td>
<td>.592</td>
</tr>
<tr>
<td>Caudate</td>
<td>1.952 (.643)</td>
<td>2.322<sup><xref ref-type="table-fn" rid="table-fn3-1352458512459289">‡</xref></sup> (.615)</td>
<td>1.647 (.614)</td>
<td>.078</td>
</tr>
<tr>
<td>Putamen</td>
<td>1.479 (.545)</td>
<td>1.679 (.419)</td>
<td>1.482 (.776)</td>
<td>.515</td>
</tr>
<tr>
<td>Globus pallidus</td>
<td>1.469 (.266)</td>
<td>1.547 (.190)</td>
<td>1.478 (.342)</td>
<td>.644</td>
</tr>
<tr>
<td>Thalamus</td>
<td>6.444 (.807)</td>
<td>6.160 (.569)</td>
<td>6.397 (.41)</td>
<td>.467</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>1.217 (.672)</td>
<td>1.132 (.854)</td>
<td>1.005 (.597)</td>
<td>.841</td>
</tr>
<tr>
<td>Amygdala</td>
<td>.384 (.154)</td>
<td>.505 (.334)</td>
<td>.402 (.119)</td>
<td>.327</td>
</tr>
<tr>
<td>Nucleus accumbens</td>
<td>.06 (.095)</td>
<td>.075 (.078)</td>
<td>.078 (.107)</td>
<td>.865</td>
</tr>
<tr>
<td>Red nucleus</td>
<td>.002 (.004)</td>
<td>.003 (.004)</td>
<td>.001 (.001)</td>
<td>.617</td>
</tr>
<tr>
<td>Substantia nigra</td>
<td>.031 (.022)</td>
<td>.051<sup><xref ref-type="table-fn" rid="table-fn3-1352458512459289">†</xref></sup> (.027)</td>
<td>.036 (.028)</td>
<td>.060</td>
</tr>
<tr>
<td>Pulvinar nucleus</td>
<td>.040 (.021)</td>
<td>.073<sup><xref ref-type="table-fn" rid="table-fn3-1352458512459289">††</xref><xref ref-type="table-fn" rid="table-fn3-1352458512459289">‡</xref></sup> (.021)</td>
<td>.048 (.024)</td>
<td>&lt; .001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1352458512459289">
<p><italic>n</italic> = number. All normalized deep gray matter volumes are expressed in milliliters. Differences between groups were tested for significance using analysis of variance and the Student’s <italic>t</italic>-test. * <italic>p</italic>&lt;.05, ** <italic>p</italic>&lt;.01 for OND versus HC; <sup>†</sup> <italic>p</italic>&lt;.05, <sup>††</sup> <italic>p</italic>&lt;.01 for MS versus HC; <sup>‡</sup> <italic>p</italic>&lt;.05, <sup>‡‡</sup> <italic>p</italic>&lt;.01 for MS versus OND.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>As for the normalized SDGM volume measurements (<xref ref-type="table" rid="table4-1352458512459289">Table 4</xref>), group-wise differences showed decreased volume of the pulvinar nucleus of the thalamus (<italic>p</italic>=.002, <xref ref-type="fig" rid="fig2-1352458512459289">Figure 2c</xref>), while there was also a trend for decreased putamen (<italic>p</italic>=.07) in MS patients. Pair-wise comparisons yielded significant differences only between MS patients and HC. Decreased normalized volumes were found in pulvinar nucleus of the thalamus (−15.5%, <italic>p</italic>&lt;.001, <italic>d</italic>=.77) and putamen (−9.8%, <italic>p</italic>=.017, <italic>d</italic>=.83) in MS patients.</p>
<table-wrap id="table4-1352458512459289" position="float">
<label>Table 4.</label>
<caption>
<p>Normalized volume measurements of subcortical deep gray matter (SDGM) structures of healthy control (HC) subjects and patients with adolescent multiple sclerosis (MS) or other neurologic diseases (OND).</p>
</caption>
<graphic alternate-form-of="table4-1352458512459289" xlink:href="10.1177_1352458512459289-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="4"><bold>Normalized volume</bold><hr/></th>
</tr>
<tr>
<th/>
<th align="left">HC (<italic>n</italic>=21) mean (SD)</th>
<th align="left">Adolescent MS (<italic>n</italic>=20) mean (SD)</th>
<th align="left">Adolescent OND (<italic>n</italic>=8) mean (SD)</th>
<th align="left"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total SDGM</td>
<td>49.17 (4.23)</td>
<td>46.66 (4.97)</td>
<td>46.82 (4.78)</td>
<td>.225</td>
</tr>
<tr>
<td>Caudate</td>
<td>7.85 (.87)</td>
<td>7.42 (.98)</td>
<td>7.39 (1.1)</td>
<td>.334</td>
</tr>
<tr>
<td>Putamen</td>
<td>10.42 (1.12)</td>
<td>9.4<sup><xref ref-type="table-fn" rid="table-fn4-1352458512459289">†</xref></sup> (1.32)</td>
<td>10.06 (1.75)</td>
<td>.070</td>
</tr>
<tr>
<td>Globus pallidus</td>
<td>3.67 (.39)</td>
<td>3.46 (.42)</td>
<td>3.48 (.43)</td>
<td>.267</td>
</tr>
<tr>
<td>Thalamus</td>
<td>16.34 (1.75)</td>
<td>15.62 (1.86)</td>
<td>15.39 (1.31)</td>
<td>.363</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>7.47 (.97)</td>
<td>7.31 (1.03)</td>
<td>7.02 (.72)</td>
<td>.634</td>
</tr>
<tr>
<td>Amygdala</td>
<td>2.53 (.33)</td>
<td>2.46 (.36)</td>
<td>2.62 (.16)</td>
<td>.568</td>
</tr>
<tr>
<td>Nucleus accumbens</td>
<td>.89 (.14)</td>
<td>.93 (.19)</td>
<td>.86 (.17)</td>
<td>.583</td>
</tr>
<tr>
<td>Red nucleus</td>
<td>.19 (.03)</td>
<td>.18 (.03)</td>
<td>.17 (.03)</td>
<td>.541</td>
</tr>
<tr>
<td>Substantia nigra</td>
<td>.3 (.04)</td>
<td>.28 (.03)</td>
<td>.28 (.06)</td>
<td>.595</td>
</tr>
<tr>
<td>Pulvinar nucleus</td>
<td>.51 (.06)</td>
<td>.43<sup><xref ref-type="table-fn" rid="table-fn4-1352458512459289">††</xref></sup> (.07)</td>
<td>.48 (.07)</td>
<td>.002</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1352458512459289">
<p><italic>n</italic> = number. All normalized deep gray matter volumes are expressed in milliliters. Differences between groups were tested for significance using analysis of variance and the Student’s <italic>t</italic>-test. * <italic>p</italic>&lt;.05, ** <italic>p</italic>&lt;.01 for OND versus HC; <sup>†</sup> <italic>p</italic>&lt;.05, <sup>††</sup> &lt;<italic>p</italic>.01 for MS versus HC; <sup>‡</sup> <italic>p</italic>&lt;.05, <sup>‡‡</sup> <italic>p</italic>&lt;.01 for MS versus OND.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In <xref ref-type="table" rid="table5-1352458512459289">Table 5</xref> differences between the study groups in NPTV are shown. Significant decreases in the pulvinar nucleus of the thalamus (<italic>p</italic>&lt;.001, <xref ref-type="fig" rid="fig2-1352458512459289">Figure 2d</xref>), putamen (<italic>p</italic>=.016) and caudate (<italic>p</italic>=.041) were found between the three study groups, and there was a trend for decrease in total SDGM (<italic>p</italic>=.081). Pair-wise comparisons of these structures yielded the following results: NPTV was significantly decreased in MS patients in the pulvinar nucleus of the thalamus (−21.7%, <italic>p</italic>&lt;.001, <italic>d</italic>=1.41), putamen (−14.3%, <italic>p</italic>=.005, <italic>d</italic>=1.03), caudate (−14.4%, <italic>p</italic>=.014, <italic>d</italic>=.89) and total SDGM (−8.4%, <italic>p</italic>=.028, <italic>d</italic>=.78) compared to HC. Compared to OND, MS patients also showed significantly lower NPTV in the pulvinar nucleus of the thalamus (−18.2%, <italic>p</italic>=.048, <italic>d</italic>=1.13).</p>
<table-wrap id="table5-1352458512459289" position="float">
<label>Table 5.</label>
<caption>
<p>Normal phase tissue volume (NPTV) measurements of subcortical deep gray matter (SDGM) structures of healthy control (HC) subjects and patients with adolescent multiple sclerosis (MS) or other neurologic diseases (OND).</p>
</caption>
<graphic alternate-form-of="table5-1352458512459289" xlink:href="10.1177_1352458512459289-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="4">NPTV<hr/></th>
</tr>
<tr>
<th/>
<th align="left">HC (<italic>n</italic>=21) mean (SD)</th>
<th align="left">Adolescent MS (<italic>n</italic>=20) mean (SD)</th>
<th align="left">Adolescent OND (<italic>n</italic>=8) mean (SD)</th>
<th align="left"><italic>p</italic>-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total SDGM</td>
<td>36.237 (3.666)</td>
<td>33.177<sup><xref ref-type="table-fn" rid="table-fn5-1352458512459289">†</xref></sup> (4.232)</td>
<td>34.331 (3.77)</td>
<td>.081</td>
</tr>
<tr>
<td>Caudate</td>
<td>5.957 (1.03)</td>
<td>5.096<sup><xref ref-type="table-fn" rid="table-fn5-1352458512459289">†</xref></sup> (.902)</td>
<td>5.745 (.953)</td>
<td>.041</td>
</tr>
<tr>
<td>Putamen</td>
<td>8.981 (1.154)</td>
<td>7.723<sup><xref ref-type="table-fn" rid="table-fn5-1352458512459289">††</xref></sup> (1.343)</td>
<td>8.574 (1.069)</td>
<td>.016</td>
</tr>
<tr>
<td>Globus pallidus</td>
<td>2.197 (.378)</td>
<td>1.911 (.419)</td>
<td>2.003 (.351)</td>
<td>.107</td>
</tr>
<tr>
<td>Thalamus</td>
<td>9.819 (1.323)</td>
<td>9.458 (1.475)</td>
<td>8.991 (1.181)</td>
<td>.453</td>
</tr>
<tr>
<td>Hippocampus</td>
<td>6.305 (.961)</td>
<td>6.18 (1.014)</td>
<td>6.013 (1.243)</td>
<td>.834</td>
</tr>
<tr>
<td>Amygdala</td>
<td>2.154 (.335)</td>
<td>1.949 (.57)</td>
<td>2.222 (.146)</td>
<td>.294</td>
</tr>
<tr>
<td>Nucleus accumbens</td>
<td>.821 (.162)</td>
<td>.858 (.181)</td>
<td>.781 (.17)</td>
<td>.642</td>
</tr>
<tr>
<td>Red nucleus</td>
<td>.185 (.034)</td>
<td>.176 (.029)</td>
<td>.169 (.025)</td>
<td>.511</td>
</tr>
<tr>
<td>Substantia nigra</td>
<td>.266 (.051)</td>
<td>.233 (.045)</td>
<td>.24 (.045)</td>
<td>.146</td>
</tr>
<tr>
<td>Pulvinar nucleus</td>
<td>.464 (.058)</td>
<td>.355<sup><xref ref-type="table-fn" rid="table-fn5-1352458512459289">††</xref> <xref ref-type="table-fn" rid="table-fn5-1352458512459289">‡</xref></sup> (.077)</td>
<td>.435 (.061)</td>
<td>&lt; .001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1352458512459289">
<p><italic>n</italic> = number. All volumes are expressed in milliliters. Differences between groups were tested using analysis of variance and the Student’s <italic>t</italic>-test. * <italic>p</italic>&lt;.05, ** <italic>p</italic>&lt;.01 for OND versus HC; <sup>†</sup> <italic>p</italic>&lt;.05, <sup>††</sup> &lt;<italic>p</italic>.01 for MS versus HC; <sup>‡</sup> <italic>p</italic>&lt;.05, <sup>‡‡</sup> <italic>p</italic>&lt;.01 for MS versus OND.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In MS patients, increased T2-LV and increased MP-APT of the pulvinar nucleus of the thalamus (<italic>r</italic>=.72, <italic>p</italic>&lt;.001) and putamen (<italic>r</italic>=.5, <italic>p</italic>&lt;.05) were significantly related. Increased MP-APT of the total SDGM, putamen, amygdala and nucleus accumbens were also related to increased T1-LV (<italic>p</italic>&lt;.05). Moreover, decreased NGMV was related to increased MP-APT in the thalamus (<italic>r</italic>=−.626, <italic>p</italic>&lt;.01), and increased NLVV was related to increased MP-APT in the pulvinar nucleus of the thalamus (<italic>r</italic>=−.56, <italic>p</italic>&lt;.05) in MS patients. Decreased normalized volume and NPTV measurements of several SDGM structures were associated with increased T2-LV, T1-LV and NLVV, and decreased NBV and NWMV, but not NGMV. The strongest significant correlations were detected for NPTV (<italic>r</italic>=.65 to <italic>r</italic>=.78, <italic>p</italic>&lt;.01) in the pulvinar nucleus of the thalamus, putamen and amygdala.</p>
<p>No significant relationships between conventional (T2-LV, T1-LV and global and tissue-specific atrophy measures) or SDGM volumes and SWI MRI measures, and clinical outcomes (disease duration and disability) were found in the current study.</p>
</sec>
<sec id="section14-1352458512459289" sec-type="discussion">
<title>Discussion</title>
<p>This is the first study to investigate the characteristics of iron deposition in the SDGM of adolescent MS patients using SWI-filtered phase images. An increase in both MP-APT (28.2%) and MP-APT volume (82.7%) of the pulvinar nucleus of the thalamus and other SDGM structures was observed in MS patients, compared to HC. Furthermore, we also detected significantly increased MP-APT volume in the pulvinar nucleus of the thalamus and caudate of MS patients compared to OND patients. These findings suggest that abnormal phase, indicative of increased iron content, is significantly increased in the SDGM of adolescent MS patients with particular involvement of the pulvinar nucleus of thalamus. Additionally, we found decreased NPTV and normalized volumes in the same SDGM structures, suggesting that occurrence of atrophy and iron deposition are closely interrelated in the early stages of the disease in adolescent MS patients.</p>
<p>Several MRI techniques have been used to evaluate SDGM iron deposition in adult patients with MS, including T2 hypointensity,<sup><xref ref-type="bibr" rid="bibr17-1352458512459289">17</xref></sup> relaxometry,<sup><xref ref-type="bibr" rid="bibr18-1352458512459289">18</xref>,<xref ref-type="bibr" rid="bibr19-1352458512459289">19</xref></sup> magnetic field correlation<sup><xref ref-type="bibr" rid="bibr20-1352458512459289">20</xref></sup> and SWI-filtered phase imaging.<sup><xref ref-type="bibr" rid="bibr3-1352458512459289">3</xref>,<xref ref-type="bibr" rid="bibr21-1352458512459289">21</xref></sup> In adult MS, SDGM T2 hypointensity was found to be a predictor of clinical progression and brain atrophy.<sup><xref ref-type="bibr" rid="bibr4-1352458512459289">4</xref>,<xref ref-type="bibr" rid="bibr18-1352458512459289">18</xref>,<xref ref-type="bibr" rid="bibr22-1352458512459289">22</xref></sup> Additionally, SDGM T2 hypointensity is also present in benign MS patients,<sup><xref ref-type="bibr" rid="bibr23-1352458512459289">23</xref></sup> as well as at first symptom onset.<sup><xref ref-type="bibr" rid="bibr22-1352458512459289">22</xref>,<xref ref-type="bibr" rid="bibr24-1352458512459289">24</xref></sup></p>
<p>In this study, we used an SWI-filtered phase approach, which applies a complex-space high-pass filter to reduce the effects of non-uniformities throughout the images and retain only biologically relevant localized phase shifts — the type caused by iron deposition.<sup><xref ref-type="bibr" rid="bibr11-1352458512459289">11</xref>,<xref ref-type="bibr" rid="bibr12-1352458512459289">12</xref></sup> To further avoid contamination from any remaining susceptibility artifacts and improve sensitivity, we used the MP-APT approach rather than histogram analysis (focusing entirely on quantitatively abnormal areas). Similar approaches have been employed previously in the investigation of iron deposition in adult, but not adolescent MS patients.<sup><xref ref-type="bibr" rid="bibr3-1352458512459289">3</xref>,<xref ref-type="bibr" rid="bibr21-1352458512459289">21</xref>,<xref ref-type="bibr" rid="bibr25-1352458512459289">25</xref><xref ref-type="bibr" rid="bibr26-1352458512459289"/><xref ref-type="bibr" rid="bibr27-1352458512459289"/><xref ref-type="bibr" rid="bibr28-1352458512459289"/>–<xref ref-type="bibr" rid="bibr29-1352458512459289">29</xref></sup> Use of an SWI-filtered phase approach has several advantages over T2 hypointensity measurements.<sup><xref ref-type="bibr" rid="bibr3-1352458512459289">3</xref>,<xref ref-type="bibr" rid="bibr11-1352458512459289">11</xref>,<xref ref-type="bibr" rid="bibr30-1352458512459289">30</xref></sup> SWI-filtered phase imaging is an MRI technique that can visualize tissues affected by iron deposition in the form of ferritin, deoxyhemoglobin or hemosiderin.<sup><xref ref-type="bibr" rid="bibr11-1352458512459289">11</xref></sup> Recent SWI-filtered phase imaging studies showed increased iron content in a large cohort of relapsing and progressive MS patients,<sup><xref ref-type="bibr" rid="bibr3-1352458512459289">3</xref>,<xref ref-type="bibr" rid="bibr25-1352458512459289">25</xref></sup> as well as in those with clinically isolated syndrome (CIS).<sup><xref ref-type="bibr" rid="bibr26-1352458512459289">26</xref></sup></p>
<p>Increased brain iron levels have also been observed histologically in several neurodegenerative diseases, including MS.<sup><xref ref-type="bibr" rid="bibr2-1352458512459289">2</xref></sup> Iron deposition could be derived from several sources including myelin, oligodendrocyte debris, or macrophages. Furthermore, such elevated iron content could potentially be an instigator of inflammation and disease progression,<sup><xref ref-type="bibr" rid="bibr18-1352458512459289">18</xref>,<xref ref-type="bibr" rid="bibr31-1352458512459289">31</xref></sup> possibly causing tissue damage through the generation of hydroxyl radicals.<sup><xref ref-type="bibr" rid="bibr32-1352458512459289">32</xref></sup> In the present study we demonstrated that excessive iron deposition is present at the earliest stages of MS, lending credence to the notion that the aforementioned detrimental effects could potentially cause damage and lead eventually to disease progression.</p>
<p>Iron-sensitive MRI techniques such as SWI by definition reflect indirect measurements of brain iron levels and provide an in vivo method of determining abnormal iron content. Histopathological post-mortem studies validating these techniques are emerging.<sup><xref ref-type="bibr" rid="bibr12-1352458512459289">12</xref>,<xref ref-type="bibr" rid="bibr33-1352458512459289">33</xref><xref ref-type="bibr" rid="bibr34-1352458512459289"/><xref ref-type="bibr" rid="bibr35-1352458512459289"/>–<xref ref-type="bibr" rid="bibr36-1352458512459289">36</xref></sup> A recent histopathological study evaluated the ability of 7T MRI quantitative R(2)* and phase maps to detect iron in MS patients.<sup><xref ref-type="bibr" rid="bibr35-1352458512459289">35</xref></sup> Another recent 7T MRI and histopathological study of chronic lesions showed that negative phase shifts reflect a focal iron accumulation in patients with MS.<sup><xref ref-type="bibr" rid="bibr36-1352458512459289">36</xref></sup> The ability of SWI-filtered phase images to localize and quantify brain iron content was also recently tested on five human cadaver brains by using X-ray fluorescence (XRF) mapping.<sup><xref ref-type="bibr" rid="bibr12-1352458512459289">12</xref></sup> Preliminary data from these studies suggest that estimation of the abnormal phase on SWI-filtered phase images in specific brain structures is highly related to iron content.</p>
<p>Iron content of the SDGM is known to increase during normal aging.<sup><xref ref-type="bibr" rid="bibr37-1352458512459289">37</xref></sup> Our sample’s average age was around 15 years, presumably too young for normal aging to have contributed significantly to iron deposition or atrophy. However, it has to be noted that a sample of even younger, pediatric patients could result in different outcomes. Furthermore, because the older (reference) subjects have higher brain iron concentrations, the computation of tissue with excessive iron deposition using the 2SD threshold leads to, if anything, a conservative estimation of excessively abnormal phase values in this adolescent population. It should be noted that absolute levels of MP-APT in the adolescent HC group were approximately 10–15% lower than recently reported findings in an adult sample; these findings used the identical technique,<sup><xref ref-type="bibr" rid="bibr3-1352458512459289">3</xref></sup> suggesting that adolescent subjects present with less abnormal phase than the adults, as expected.</p>
<p>Recent SWI studies showed that, in adult MS patients, iron overload is dominant in the pulvinar nucleus of the thalamus, which is in line with our results.<sup><xref ref-type="bibr" rid="bibr3-1352458512459289">3</xref>,<xref ref-type="bibr" rid="bibr26-1352458512459289">26</xref>,<xref ref-type="bibr" rid="bibr27-1352458512459289">27</xref>,<xref ref-type="bibr" rid="bibr38-1352458512459289">38</xref></sup> We found highly significant increases in the pulvinar MP-APT and MP-APT volume, and decreases in normalized volume and NPTV of this SDGM structure. The increased MP-APT, MP-APT volume and decreased NPTV and normalized volume of this region were strongly related to brain atrophy and lesion burden MRI indices. Thalamic GM loss in adolescent MS patients was detected in several studies.<sup><xref ref-type="bibr" rid="bibr7-1352458512459289">7</xref>,<xref ref-type="bibr" rid="bibr8-1352458512459289">8</xref></sup> However, the findings from the current study in adolescent MS patients, and in the recently concluded study in CIS patients,<sup><xref ref-type="bibr" rid="bibr26-1352458512459289">26</xref></sup> suggest that significant thalamic damage is confined specifically to the pulvinar nucleus of the thalamus at the earliest stages of the disease. The nature of this phenomenon has to be better understood in future studies. A number of other studies showed thalamic involvement in patients at first clinical onset.<sup><xref ref-type="bibr" rid="bibr39-1352458512459289">39</xref>,<xref ref-type="bibr" rid="bibr40-1352458512459289">40</xref></sup> One study estimated thalamic neuronal loss in patients with MS using a histopathology postmortem approach, and found that thalamic neuronal loss in MS can be substantial (30–35% reduction).<sup><xref ref-type="bibr" rid="bibr41-1352458512459289">41</xref></sup></p>
<p>Several adult MS studies using different iron-based imaging techniques showed increased iron content in other SDGM structures such as the putamen, globus pallidus and caudate.<sup><xref ref-type="bibr" rid="bibr3-1352458512459289">3</xref>,<xref ref-type="bibr" rid="bibr4-1352458512459289">4</xref>,<xref ref-type="bibr" rid="bibr21-1352458512459289">21</xref>,<xref ref-type="bibr" rid="bibr26-1352458512459289">26</xref></sup> A recent study showed increased T2 hypointensity in the left caudate of adolescent MS patients.<sup><xref ref-type="bibr" rid="bibr10-1352458512459289">10</xref></sup> In contrast, our results did not show a significant difference between study groups in caudate MP-APT; however, significantly increased MP-APT volume and decreased NPTV were observed in this structure in MS patients when compared to OND patients and HC. In the current study, multiple structures showed increased iron content in MS patients, with MP-APT in total SDGM increasing by 11.2% compared to HC. This suggests that iron deposition occurs in most structures, with a predilection for the pulvinar nucleus of the thalamus, thalamus, caudate and putamen.</p>
<p>Iron deposition may be an epiphenomenon of the MS disease process or may be related to inflammation. In a recent study, the relationship between inflammation and iron deposition was investigated using an original animal model labeled as “cerebral experimental autoimmune encephalomyelitis,” which develops “CNS perivascular iron deposits.”<sup><xref ref-type="bibr" rid="bibr42-1352458512459289">42</xref></sup> It was reported that inflammatory cell infiltrates were associated with perivascular iron deposits; however, inflammatory cells were also observed without associated iron deposits. These findings support a pathogenic mechanism whereby vascular inflammation leads to consequent iron deposition. The association between T2-LV and T1-LV accumulation and increased MP-APT and MP-APT volume and decreased normalized volumes and NPTV in various SDGM structures, especially in the pulvinar nucleus of the thalamus and putamen in our adolescent MS cohort with three years of disease duration, provides novel information indicating that iron deposition and atrophy development in the basal ganglia are closely related to inflammatory processes, as measured by T2 and T1 lesion accumulation. Similarly, in a cohort of CIS patients an association was recently found between inflammation, as measured by T2 and gadolinium (Gd)-enhancing lesions, and increased MP-APT volume and decreased NPTV in various SDGM structures, most prominently the pulvinar nucleus of the thalamus.<sup><xref ref-type="bibr" rid="bibr26-1352458512459289">26</xref></sup> However, in the current study, Gd contrast was not used consistently in all patients since it was not diagnostic in nature. Therefore, we cannot elucidate at this time whether iron deposition is associated with acute or more chronic inflammation in adolescent MS patients.</p>
<p>It is interesting to note that no differences in whole brain, GM or WM volumes were detected between MS patients, OND patients and HC in the present study, suggesting that regional atrophy of specific subcortical structures may be involved early in the MS disease process and predict disease progression.<sup><xref ref-type="bibr" rid="bibr7-1352458512459289">7</xref>,<xref ref-type="bibr" rid="bibr9-1352458512459289">9</xref>,<xref ref-type="bibr" rid="bibr10-1352458512459289">10</xref>,<xref ref-type="bibr" rid="bibr24-1352458512459289">24</xref>,<xref ref-type="bibr" rid="bibr30-1352458512459289">30</xref>,<xref ref-type="bibr" rid="bibr39-1352458512459289">39</xref>,<xref ref-type="bibr" rid="bibr43-1352458512459289">43</xref></sup> It may be that increased levels of iron are secondary to regional atrophy and inflammation. However, it must be noted that it has been found that iron deposition in the SDGM is increased among CIS patients, even though structure-specific atrophy is not yet observed at such an early disease stage.<sup><xref ref-type="bibr" rid="bibr26-1352458512459289">26</xref></sup></p>
<p>Using a large cohort of relapsing and progressive MS patients, it has been shown that increased iron content in the SDGM is associated more with disability progression than conventional MRI metrics such as lesion burden or brain atrophy.<sup><xref ref-type="bibr" rid="bibr5-1352458512459289">5</xref></sup> Relatively minimal disability and being in an early stage of the disease in our cohort may explain the lack of a relationship between clinical and MRI outcomes in the present study.</p>
<p>There are multiple limitations in the present study that should be considered when interpreting the current findings: 1) The sample size was relatively small and further research with larger samples is warranted. In particular, the limited number of OND patients enrolled in the study made comparisons difficult with the MS and HC groups. 2) Although neurovascular, neuromuscular and neuroinflammatory OND were purposely grouped together in this study, it is important to investigate whether iron deposition may vary between different OND types. 3) No lesions were found in the SDGM of MS or OND patients; however, more sensitive sequences for GM lesion detection, like double inversion recovery (DIR), were not applied in the present study. A recent histopathological-MRI study showed relatively low sensitivity of DIR for lesion detection in the SDGM.<sup><xref ref-type="bibr" rid="bibr44-1352458512459289">44</xref></sup> 4) No one-on-one age- and sex-matching between MS patients and HC was performed; however, those demographic characteristics were similar between the two groups. 5) The small size of the pulvinar nucleus of thalamus may have potentially influenced the reproducibility of the measurements. However, it has to be noted that in the previous study it was shown that various measurements of SDGM structures, including pulvinar nucleus of thalamus, can be reproduced with high scan-rescan reliability.<sup><xref ref-type="bibr" rid="bibr3-1352458512459289">3</xref></sup> In addition, all the MRI analyses were performed in this study in a blinded fashion by a single operator.</p>
<p>In conclusion, we showed the presence of abnormal phase indicative of excessive iron levels in the SDGM in adolescent MS patients using SWI-filtered phase. The SDGM, and especially pulvinar nucleus of thalamus, are affected in early onset MS.</p>
</sec>
</body>
<back>
<ack>
<p>The authors wish to thank Eve Salczynski for technical assistance in the preparation of this manuscript.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding statement</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare no conflicts of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458512459289">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geurts</surname><given-names>JJ</given-names></name>
<name><surname>Barkhof</surname><given-names>F</given-names></name>
</person-group>. <article-title>Grey matter pathology in multiple sclerosis</article-title>. <source>Lancet Neurol</source> <year>2008</year>; <volume>7</volume>: <fpage>841</fpage>–<lpage>851</lpage>.</citation>
</ref>
<ref id="bibr2-1352458512459289">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>LeVine</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Iron deposits in multiple sclerosis and Alzheimer’s disease brains</article-title>. <source>Brain Res</source> <year>1997</year>; <volume>760</volume>: <fpage>298</fpage>–<lpage>303</lpage>.</citation>
</ref>
<ref id="bibr3-1352458512459289">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zivadinov</surname><given-names>R</given-names></name>
<name><surname>Heininen-Brown</surname><given-names>M</given-names></name>
<name><surname>Schirda</surname><given-names>CV</given-names></name>
<etal/>
</person-group>. <article-title>Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: A case-control study</article-title>. <source>Neuroimage</source> <year>2012</year>; <volume>59</volume>: <fpage>331</fpage>–<lpage>339</lpage>.</citation>
</ref>
<ref id="bibr4-1352458512459289">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bakshi</surname><given-names>R</given-names></name>
<name><surname>Benedict</surname><given-names>RHB</given-names></name>
<name><surname>Bermel</surname><given-names>RA</given-names></name>
<etal/>
</person-group>. <article-title>T2 hypointensity in the deep gray matter of patients with multiple sclerosis: A quantitative magnetic resonance imaging study</article-title>. <source>Arch Neurol</source> <year>2002</year>; <volume>59</volume>: <fpage>62</fpage>.</citation>
</ref>
<ref id="bibr5-1352458512459289">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hagemeier</surname><given-names>J</given-names></name>
<name><surname>Weinstock-Guttman</surname><given-names>B</given-names></name>
<name><surname>Heininen Brown</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Gray matter SWI-filtered phase and atrophy are associated with disability in MS</article-title>. <source>Front Biosci</source>, in press.</citation>
</ref>
<ref id="bibr6-1352458512459289">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yeh</surname><given-names>EA</given-names></name>
<name><surname>Weinstock-Guttman</surname><given-names>B</given-names></name>
<name><surname>Ramanathan</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis</article-title>. <source>Brain</source> <year>2009</year>; <volume>132</volume>: <fpage>3392</fpage>–<lpage>3400</lpage>.</citation>
</ref>
<ref id="bibr7-1352458512459289">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aubert-Broche</surname><given-names>B</given-names></name>
<name><surname>Fonov</surname><given-names>V</given-names></name>
<name><surname>Ghassemi</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Regional brain atrophy in children with multiple sclerosis</article-title>. <source>Neuroimage</source> <year>2011</year>; <volume>58</volume>: <fpage>409</fpage>–<lpage>415</lpage>.</citation>
</ref>
<ref id="bibr8-1352458512459289">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kerbrat</surname><given-names>A</given-names></name>
<name><surname>Aubert-Broche</surname><given-names>B</given-names></name>
<name><surname>Fonov</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>Reduced head and brain size for age and disproportionately smaller thalami in child-onset MS</article-title>. <source>Neurology</source> <year>2012</year>; <volume>78</volume>: <fpage>194</fpage>–<lpage>201</lpage>.</citation>
</ref>
<ref id="bibr9-1352458512459289">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mesaros</surname><given-names>S</given-names></name>
<name><surname>Rocca</surname><given-names>MA</given-names></name>
<name><surname>Absinta</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Evidence of thalamic gray matter loss in pediatric multiple sclerosis</article-title>. <source>Neurology</source> <year>2008</year>; <volume>70</volume>: <fpage>1107</fpage>–<lpage>1112</lpage>.</citation>
</ref>
<ref id="bibr10-1352458512459289">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ceccarelli</surname><given-names>A</given-names></name>
<name><surname>Rocca</surname><given-names>MA</given-names></name>
<name><surname>Perego</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Deep grey matter T2 hypo-intensity in patients with paediatric multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>702</fpage>–<lpage>707</lpage>.</citation>
</ref>
<ref id="bibr11-1352458512459289">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haacke</surname><given-names>EM</given-names></name>
<name><surname>Xu</surname><given-names>Y</given-names></name>
<name><surname>Cheng</surname><given-names>YC</given-names></name>
<etal/>
</person-group>. <article-title>Susceptibility weighted imaging (SWI)</article-title>. <source>Magn Reson Med</source> <year>2004</year>; <volume>52</volume>: <fpage>612</fpage>–<lpage>618</lpage>.</citation>
</ref>
<ref id="bibr12-1352458512459289">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hopp</surname><given-names>K</given-names></name>
<name><surname>Popescu</surname><given-names>BF</given-names></name>
<name><surname>McCrea</surname><given-names>RP</given-names></name>
<etal/>
</person-group>. <article-title>Brain iron detected by SWI high pass filtered phase calibrated with synchrotron X-ray fluorescence</article-title>. <source>J Magn Reson Imaging</source> <year>2010</year>; <volume>31</volume>: <fpage>1346</fpage>–<lpage>1354</lpage>.</citation>
</ref>
<ref id="bibr13-1352458512459289">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Polman</surname><given-names>CH</given-names></name>
<name><surname>Reingold</surname><given-names>SC</given-names></name>
<name><surname>Banwell</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria</article-title>. <source>Ann Neurol</source> <year>2011</year>; <volume>69</volume>: <fpage>292</fpage>–<lpage>302</lpage>.</citation>
</ref>
<ref id="bibr14-1352458512459289">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Patenaude</surname><given-names>B</given-names></name>
<name><surname>Smith</surname><given-names>S</given-names></name>
<name><surname>Kennedy</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>A Bayesian model of shape and appearance for subcortical brain segmentation</article-title>. <source>Neuroimage</source> <year>2011</year>; <volume>56</volume>: <fpage>907</fpage>–<lpage>922</lpage>.</citation>
</ref>
<ref id="bibr15-1352458512459289">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Batista</surname><given-names>S</given-names></name>
<name><surname>Zivadinov</surname><given-names>R</given-names></name>
<name><surname>Hoogs</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis</article-title>. <source>J Neurol</source> <year>2012</year>; <volume>259</volume>: <fpage>139</fpage>–<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr16-1352458512459289">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zivadinov</surname><given-names>R</given-names></name>
<name><surname>Rudick</surname><given-names>RA</given-names></name>
<name><surname>De Masi</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Effects of IV methylprednisolone on brain atrophy in relapsing–remitting MS</article-title>. <source>Neurology</source> <year>2001</year>; <volume>57</volume>: <fpage>1239</fpage>–<lpage>1247</lpage>.</citation>
</ref>
<ref id="bibr17-1352458512459289">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bakshi</surname><given-names>R</given-names></name>
<name><surname>Shaikh</surname><given-names>ZA</given-names></name>
<name><surname>Janardhan</surname><given-names>V</given-names></name>
</person-group>. <article-title>MRI T2 shortening (‘black T2’) in multiple sclerosis: Frequency, location, and clinical correlation</article-title>. <source>Neuroreport</source> <year>2000</year>; <volume>11</volume>: <fpage>15</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr18-1352458512459289">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khalil</surname><given-names>M</given-names></name>
<name><surname>Langkammer</surname><given-names>C</given-names></name>
<name><surname>Ropele</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Determinants of brain iron in multiple sclerosis: A quantitative 3T MRI study</article-title>. <source>Neurology</source> <year>2011</year>; <volume>77</volume>: <fpage>1691</fpage>–<lpage>1697</lpage>.</citation>
</ref>
<ref id="bibr19-1352458512459289">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Neema</surname><given-names>M</given-names></name>
<name><surname>Goldberg-Zimring</surname><given-names>D</given-names></name>
<name><surname>Guss</surname><given-names>ZD</given-names></name>
<etal/>
</person-group>. <article-title>3 T MRI relaxometry detects T2 prolongation in the cerebral normal-appearing white matter in multiple sclerosis</article-title>. <source>Neuroimage</source> <year>2009</year>; <volume>46</volume>: <fpage>633</fpage>–<lpage>641</lpage>.</citation>
</ref>
<ref id="bibr20-1352458512459289">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ge</surname><given-names>Y</given-names></name>
<name><surname>Jensen</surname><given-names>JH</given-names></name>
<name><surname>Lu</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging</article-title>. <source>AJNR Am J Neuroradiol</source> <year>2007</year>; <volume>28</volume>: <fpage>1639</fpage>–<lpage>1644</lpage>.</citation>
</ref>
<ref id="bibr21-1352458512459289">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hammond</surname><given-names>KE</given-names></name>
<name><surname>Metcalf</surname><given-names>M</given-names></name>
<name><surname>Carvajal</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron</article-title>. <source>Ann Neurol</source> <year>2008</year>; <volume>64</volume>: <fpage>707</fpage>–<lpage>713</lpage>.</citation>
</ref>
<ref id="bibr22-1352458512459289">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khalil</surname><given-names>M</given-names></name>
<name><surname>Enzinger</surname><given-names>C</given-names></name>
<name><surname>Langkammer</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing–remitting multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2009</year>; <volume>15</volume>: <fpage>1048</fpage>–<lpage>1054</lpage>.</citation>
</ref>
<ref id="bibr23-1352458512459289">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ceccarelli</surname><given-names>A</given-names></name>
<name><surname>Filippi</surname><given-names>M</given-names></name>
<name><surname>Neema</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2009</year>; <volume>15</volume>: <fpage>678</fpage>–<lpage>686</lpage>.</citation>
</ref>
<ref id="bibr24-1352458512459289">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ceccarelli</surname><given-names>A</given-names></name>
<name><surname>Rocca</surname><given-names>MA</given-names></name>
<name><surname>Neema</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2010</year>; <volume>16</volume>: <fpage>39</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr25-1352458512459289">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Habib</surname><given-names>CA</given-names></name>
<name><surname>Liu</surname><given-names>M</given-names></name>
<name><surname>Bawany</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Assessing abnormal iron content in the deep gray matter of patients with multiple sclerosis versus healthy controls</article-title>. <source>AJNR Am J Neuroradiol</source> <year>2012</year>; <volume>33</volume>: <fpage>252</fpage>–<lpage>258</lpage>. Epub 24 November 2011.</citation>
</ref>
<ref id="bibr26-1352458512459289">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hagemeier</surname><given-names>J</given-names></name>
<name><surname>Weinstock-Guttman</surname><given-names>B</given-names></name>
<name><surname>Bergsland</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Iron deposition on SWI filtered phase in the subcortical deep gray matter of clinically isolated syndrome patients may precede structure-specific atrophy</article-title>. <source>AJNR Am J Neuroradiol</source>. Epub ahead of print 25 July 2012.</citation>
</ref>
<ref id="bibr27-1352458512459289">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lebel</surname><given-names>RM</given-names></name>
<name><surname>Eissa</surname><given-names>A</given-names></name>
<name><surname>Seres</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Quantitative high field imaging of sub-cortical gray matter in multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2012</year>; <volume>18</volume>: <fpage>433</fpage>–<lpage>441</lpage>. Epub 27 October 2011.</citation>
</ref>
<ref id="bibr28-1352458512459289">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eissa</surname><given-names>A</given-names></name>
<name><surname>Lebel</surname><given-names>RM</given-names></name>
<name><surname>Korzan</surname><given-names>JR</given-names></name>
<etal/>
</person-group>. <article-title>Detecting lesions in multiple sclerosis at 4.7 tesla using phase susceptibility-weighting and T2-weighting</article-title>. <source>J Magn Reson Imaging</source> <year>2009</year>; <volume>30</volume>: <fpage>737</fpage>–<lpage>742</lpage>.</citation>
</ref>
<ref id="bibr29-1352458512459289">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hagemeier</surname><given-names>J</given-names></name>
<name><surname>Heininen-Brown</surname><given-names>M</given-names></name>
<name><surname>Poloni</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging. A case control study</article-title>. <source>J Magn Reson Imag</source> <year>2012</year>; <volume>36</volume>: <fpage>73</fpage>–<lpage>83</lpage>. Epub 7 March 2010. DOI: <pub-id pub-id-type="doi">10.1002/jmri.23603</pub-id>.</citation>
</ref>
<ref id="bibr30-1352458512459289">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ropele</surname><given-names>S</given-names></name>
<name><surname>de Graaf</surname><given-names>W</given-names></name>
<name><surname>Khalil</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>MRI assessment of iron deposition in multiple sclerosis</article-title>. <source>J Magn Reson Imaging</source> <year>2011</year>; <volume>34</volume>: <fpage>13</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr31-1352458512459289">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zivadinov</surname><given-names>R</given-names></name>
<name><surname>Weinstock-Guttman</surname><given-names>B</given-names></name>
<name><surname>Pirko</surname><given-names>I</given-names></name>
</person-group>. <article-title>Iron deposition and inflammation in multiple sclerosis. Which one comes first?</article-title> <source>BMC Neurosci</source> <year>2011</year>; <volume>12</volume>: <fpage>60</fpage>.</citation>
</ref>
<ref id="bibr32-1352458512459289">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khalil</surname><given-names>M</given-names></name>
<name><surname>Teunissen</surname><given-names>C</given-names></name>
<name><surname>Langkammer</surname><given-names>C</given-names></name>
</person-group>. <article-title>Iron and neurodegeneration in multiple sclerosis</article-title>. <source>Mult Scler Int</source> <year>2011</year>: <fpage>606807</fpage>. Epub 10 February 2011.</citation>
</ref>
<ref id="bibr33-1352458512459289">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Langkammer</surname><given-names>C</given-names></name>
<name><surname>Krebs</surname><given-names>N</given-names></name>
<name><surname>Goessler</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Quantitative MR imaging of brain iron: A postmortem validation study</article-title>. <source>Radiology</source> <year>2010</year>; <volume>257</volume>: <fpage>455</fpage>–<lpage>462</lpage>.</citation>
</ref>
<ref id="bibr34-1352458512459289">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yao</surname><given-names>B</given-names></name>
<name><surname>Li</surname><given-names>TQ</given-names></name>
<name><surname>Gelderen</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Susceptibility contrast in high field MRI of human brain as a function of tissue iron content</article-title>. <source>Neuroimage</source> <year>2009</year>; <volume>44</volume>: <fpage>1259</fpage>–<lpage>1266</lpage>.</citation>
</ref>
<ref id="bibr35-1352458512459289">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bagnato</surname><given-names>F</given-names></name>
<name><surname>Hametner</surname><given-names>S</given-names></name>
<name><surname>Yao</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Tracking iron in multiple sclerosis: A combined imaging and histopathological study at 7 Tesla</article-title>. <source>Brain</source> <year>2011</year>; <volume>134</volume>: <fpage>3602</fpage>–<lpage>3615</lpage>.</citation>
</ref>
<ref id="bibr36-1352458512459289">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yao</surname><given-names>B</given-names></name>
<name><surname>Bagnato</surname><given-names>F</given-names></name>
<name><surname>Matsuura</surname><given-names>E</given-names></name>
<etal/>
</person-group>. <article-title>Chronic multiple sclerosis lesions: Characterization with high-field-strength MR imaging</article-title>. <source>Radiology</source> <year>2012</year>; <volume>262</volume>: <fpage>206</fpage>–<lpage>215</lpage>.</citation>
</ref>
<ref id="bibr37-1352458512459289">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Martin</surname><given-names>WR</given-names></name>
<name><surname>Ye</surname><given-names>FQ</given-names></name>
<name><surname>Allen</surname><given-names>PS</given-names></name>
</person-group>. <article-title>Increasing striatal iron content associated with normal aging</article-title>. <source>Mov Disord</source> <year>1998</year>; <volume>13</volume>: <fpage>281</fpage>–<lpage>286</lpage>.</citation>
</ref>
<ref id="bibr38-1352458512459289">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haacke</surname><given-names>EM</given-names></name>
<name><surname>Garbern</surname><given-names>J</given-names></name>
<name><surname>Miao</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Iron stores and cerebral veins in MS studied by susceptibility weighted imaging</article-title>. <source>Int Angiol</source> <year>2010</year>; <volume>29</volume>: <fpage>149</fpage>–<lpage>157</lpage>.</citation>
</ref>
<ref id="bibr39-1352458512459289">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Calabrese</surname><given-names>M</given-names></name>
<name><surname>Rinaldi</surname><given-names>F</given-names></name>
<name><surname>Mattisi</surname><given-names>I</given-names></name>
<etal/>
</person-group>. <article-title>The predictive value of gray matter atrophy in clinically isolated syndromes</article-title>. <source>Neurology</source> <year>2011</year>; <volume>77</volume>: <fpage>257</fpage>–<lpage>263</lpage>.</citation>
</ref>
<ref id="bibr40-1352458512459289">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Henry</surname><given-names>RG</given-names></name>
<name><surname>Shieh</surname><given-names>M</given-names></name>
<name><surname>Amirbekian</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Connecting white matter injury and thalamic atrophy in clinically isolated syndromes</article-title>. <source>J Neurol Sci</source> <year>2009</year>; <volume>282</volume>: <fpage>61</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr41-1352458512459289">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cifelli</surname><given-names>A</given-names></name>
<name><surname>Arridge</surname><given-names>M</given-names></name>
<name><surname>Jezzard</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Thalamic neurodegeneration in multiple sclerosis</article-title>. <source>Ann Neurol</source> <year>2002</year>; <volume>52</volume>: <fpage>650</fpage>–<lpage>653</lpage>.</citation>
</ref>
<ref id="bibr42-1352458512459289">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Williams</surname><given-names>R</given-names></name>
<name><surname>Rohr</surname><given-names>AM</given-names></name>
<name><surname>Wang</surname><given-names>WT</given-names></name>
<etal/>
</person-group>. <article-title>Iron deposition is independent of cellular inflammation in a cerebral model of multiple sclerosis</article-title>. <source>BMC Neurosci</source> <year>2011</year>; <volume>12</volume>: <fpage>59</fpage>.</citation>
</ref>
<ref id="bibr43-1352458512459289">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Till</surname><given-names>C</given-names></name>
<name><surname>Ghassemi</surname><given-names>R</given-names></name>
<name><surname>Aubert-Broche</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>MRI correlates of cognitive impairment in childhood-onset multiple sclerosis</article-title>. <source>Neuropsychology</source> <year>2011</year>; <volume>25</volume>: <fpage>319</fpage>–<lpage>332</lpage>.</citation>
</ref>
<ref id="bibr44-1352458512459289">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Seewann</surname><given-names>A</given-names></name>
<name><surname>Kooi</surname><given-names>EJ</given-names></name>
<name><surname>Roosendaal</surname><given-names>SD</given-names></name>
<etal/>
</person-group>. <article-title>Postmortem verification of MS cortical lesion detection with 3D DIR</article-title>. <source>Neurology</source> <year>2012</year>; <volume>78</volume>: <fpage>302</fpage>–<lpage>308</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>